Creon Related Published Studies
Well-designed clinical trials related to Creon (Amylase / Lipase / Protease)
Pancrelipase delayed-release capsules (CREON) for exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery: A double-blind randomized trial. [2010.10]
Pancrelipase Delayed-Release Capsules (CREON) for Exocrine Pancreatic Insufficiency due to Chronic Pancreatitis or Pancreatic Surgery: A Double-Blind Randomized Trial. [2010.05.25]
Efficacy and safety of Creon 24,000 in subjects with exocrine pancreatic insufficiency due to cystic fibrosis. [2009.12]
The effects of oral pancreatic enzymes (Creon 10 capsule) on steatorrhea: a multicenter, placebo-controlled, parallel group trial in subjects with chronic pancreatitis. [2006.08]
Creon 10,000 Minimicrospheres vs. Creon 8,000 microspheres--an open randomised crossover preference study. [2002.12]
[Comparative clinical study of Neopanpur and Creon] [1994.01.02]
Well-designed clinical trials possibly related to Creon (Amylase / Lipase / Protease)
Treatment of infants and toddlers with cystic fibrosis-related pancreatic insufficiency and fat malabsorption with pancrelipase MT. [2011.07]
Gastric emptying, incretin hormone secretion, and postprandial glycemia in cystic fibrosis--effects of pancreatic enzyme supplementation. [2011.05]
Efficacy of a novel pancreatic enzyme product, EUR-1008 (Zenpep), in patients with exocrine pancreatic insufficiency due to chronic pancreatitis. [2011.04]
Efficacy and tolerability of a new formulation of pancrelipase delayed-release capsules in children aged 7 to 11 years with exocrine pancreatic insufficiency and cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled, two-period crossover, superiority study. [2010.01]
Efficacy and tolerability of a new formulation of pancrelipase delayed-release
capsules in children aged 7 to 11 years with exocrine pancreatic insufficiency
and cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled,
two-period crossover, superiority study. [2010]
EUR-1008 pancreatic enzyme replacement is safe and effective in patients with cystic fibrosis and pancreatic insufficiency. [2009.12]
EUR-1008 pancreatic enzyme replacement is safe and effective in patients with cystic fibrosis and pancreatic insufficiency. [2009.08.14]
Efficacy of lower than standard doses of pancreatic enzyme supplementation therapy during acid inhibition in patients with pancreatic exocrine insufficiency. [2006.09]
An enteric-coated high-buffered pancrelipase reduces steatorrhea in patients with cystic fibrosis: a prospective, randomized study. [2006.08]
Health effects of ultraviolet irradiation in asthmatic children's homes. [2006.05]
Enteric-coated pancreatic enzyme with bicarbonate is equal to standard enteric-coated enzyme in treating malabsorption in cystic fibrosis. [2006.03]
Effect of peptide YY on pancreatico-biliary secretion in humans. [2005.08]
Combining unprotected pancreatic enzymes with pH-sensitive enteric-coated microspheres does not improve nutrient digestion in patients with cystic fibrosis. [2005.04]
Ulinastatin for pancreatitis after endoscopic retrograde cholangiopancreatography: a randomized, controlled trial. [2005.04]
Effects of copper-bearing montmorillonite on growth performance, digestive enzyme activities, and intestinal microflora and morphology of male broilers. [2004.11]
Omega-3 fatty acids improve liver and pancreas function in postoperative cancer patients. [2004.09.10]
Ranitidine and omeprazole as adjuvant therapy to pancrelipase to improve fat absorption in patients with cystic fibrosis. [2002.07]
Clinical evaluation of oral administration of a cholecystokinin-A receptor antagonist (loxiglumide) to patients with acute, painful attacks of chronic pancreatitis: a multicenter dose-response study in Japan. [2002.07]
The exacerbation of pancreatic endocrine dysfunction by potent pancreatic exocrine supplements in patients with chronic pancreatitis. [2001.04]
A comparison of the efficacy and tolerance of pancrelipase and placebo in the treatment of steatorrhea in cystic fibrosis patients with clinical exocrine pancreatic insufficiency. [2000.08]
Digestive and bacterial enzyme activities in broilers fed diets supplemented with Lactobacillus cultures. [2000.06]
Pancreatic supplements reduce symptomatic response of healthy subjects to a high fat meal. [1999.07]
The effect of pancreatic enzyme supplementation in patients with steatorrhoea after total gastrectomy. [1999.03]
Lipid digestion in cystic fibrosis: comparison of conventional and high-lipase enzyme therapy using the mixed-triglyceride breath test. [1998.04]
Influence of high-dose pancreatic enzyme treatment on pancreatic function in healthy volunteers. [1998.04]
Assessment of the effectiveness of drug therapies on nutritional status in the elderly: "concerning a randomised, double-blind clinical study of the activity of pancreatic extracts and a placebo during the renutrition of elderly subjects suffering from protein caloric undernutrition". [1998]
Effect of acute hyperglycaemia on basal and fat-induced exocrine pancreatic secretion in humans. [1997.12]
Efficacy of enzyme supplementation after surgery for chronic pancreatitis. [1997.03]
M1-muscarinic mechanisms regulate interdigestive cycling of motor and secretory activity in human upper gut. [1996.10]
Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. Gabexate in digestive endoscopy--Italian Group. [1996.09.26]
Comparative evaluation of a high lipase pancreatic enzyme preparation and a standard pancreatic supplement for treating exocrine pancreatic insufficiency in chronic pancreatitis. [1996.07]
Pancreatic enzyme supplementation in acute pancreatitis. [1995.06]
Comparison of a high lipase pancreatic enzyme extract with a regular pancreatin preparation in adult cystic fibrosis patients. [1994.12]
Comparative effects of adjuvant cimetidine and omeprazole during pancreatic enzyme replacement therapy. [1994.05]
Cyclosporin pharmacokinetics in heart-lung transplant recipients with cystic fibrosis. Effects of pancreatic enzymes and ranitidine. [1994]
Comparative in vitro and in vivo studies of enteric-coated pancrelipase preparations for pancreatic insufficiency. [1993.11]
High dose Nutrizym 22 in cystic fibrosis. [1993.09]
A double blind lipase for lipase comparison of a high lipase and standard pancreatic enzyme preparation in cystic fibrosis. [1993.02]
A comparison of two pancreatin microsphere preparations in cystic fibrosis. [1992.03.25]
Therapeutic potential and clinical efficacy of acid-resistant fungal lipase in the treatment of pancreatic steatorrhoea due to cystic fibrosis. [1992]
Two enteric coated microspheres in cystic fibrosis. [1990.06]
Feedback regulation of stimulated pancreatic enzyme secretion during intraduodenal perfusion of trypsin in man. [1988.06]
Efficacy of pancreatic enzyme supplementation in children with cystic fibrosis: comparison of two preparations by random crossover study and a retrospective study of the same patients at two different ages. [1988]
Other research related to Creon (Amylase / Lipase / Protease)
A 6-month, open-label clinical trial of pancrelipase delayed-release capsules (Creon) in patients with exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery. [2011.05]
Administration of CREON(R) pancrelipase pellets via gastrostomy tube is feasible with no loss of gastric resistance or lipase activity: an in vitro study. [2011]
CREON (Pancrelipase Delayed-Release Capsules) for the treatment of exocrine pancreatic insufficiency. [2010.12]
Safety and tolerability of a new formulation of pancrelipase delayed-release capsules (CREON) in children under seven years of age with exocrine pancreatic insufficiency due to cystic fibrosis: an open-label, multicentre, single-treatment-arm study. [2010]
Efficacy and safety of Creon(R) 24,000 in subjects with exocrine pancreatic insufficiency due to cystic fibrosis. [2009.10.06]
Efficacy and tolerability of Creon for Children in infants and toddlers with pancreatic exocrine insufficiency caused by cystic fibrosis: an open-label, single-arm, multicenter study. [2009.08]
The enzyme levels in blood are not affected by oral administration of a pancreatic enzyme preparation (Creon 10,000) in pancreas-insufficient pigs. [2004.01]
Hyperamylasemia and subclinical pancreatitis after cardiac surgery. [2001.07]
Idiopathic hyperamylasemia. [1998.07]
[Trypsin and alpha-amylase activity in the pancreas of guinea pigs. V. Effects of administration of vitamin A and B 2 during the larval stage of ascariasis] [1991]
Other possibly related research studies
[The role of orlistat in the treatment of obesity] [2005.03.13]
Experiments to optimize enzyme substitution therapy in pancreatic duct-ligated pigs. [2005.04]
Skin prick test reactivity to supplemental enzymes in cystic fibrosis and pancreatic insufficiency. [2005.02]
The secretagogue effect of the poison from Centruroides limpidus limpidus on the pancreas of mice and the antagonistic action of the Bouvardia ternifolia extract. [2005.01]
Fibrosing colonopathy in an adult cystic fibrosis patient after discontinuing pancreatic enzyme therapy. [2004.09]
A high prevalence of organ-specific autoimmunity in patients with bipolar disorder. [2004.10.01]
Selective decreases in amphetamine self-administration and regulation of dopamine transporter function in diabetic rats. [2003.02]
Pancreatic metallothionein-I may play a role in zinc homeostasis during maternal dietary zinc deficiency in mice. [2003.01]
The development of a clinical syndrome of asymptomatic pancreatitis and eosinophilia after treatment with clozapine in schizophrenia: implications for clinical care, recognition and management. [2002.12]
Pancreatic toxicity after liposomal amphotericin B. [2002.06]
Postcibal gastric emptying of pancreatin pellets: effects of dose and meal oil. [2001.09]
Efficacy of oral pancreatic enzyme therapy for the treatment of fat malabsorption in HIV-infected patients. [2001.10]
Pancreatic enzyme replacement therapy. [2001.04]
Defective dietary fat processing in transgenic mice lacking aquaporin-1 water channels. [2001.01]
Diet stimulation as a synergistic factor of aggravation in a pancreatic bile duct ligation-induced rat pancreatitis model. [2000.11]
Comparison of two enteric coated microsphere preparations in the treatment of pancreatic exocrine insufficiency caused by cystic fibrosis. [2000.06]
Acquired segmental megacolon in an adult patient with cystic fibrosis. [2000.02]
Prospective, long-term study of fat-soluble vitamin status in children with cystic fibrosis identified by newborn screen. [1999.11]
Enzymatic therapy in patients with chronic pancreatitis. [1999.09]
Colonic wall thickening is related to age and not dose of high strength pancreatin microspheres in children with cystic fibrosis. [1999.02]
Colonic wall thickness, pancreatic enzyme dose and type of preparation in cystic fibrosis. [1998.10]
Oral pancreatic enzyme therapy in the control of diabetes mellitus in tropical calculous pancreatitis. [1998.08]
Faecal bile acid and dietary residue excretion in cystic fibrosis: age group variations. [1998.09]
Effects of pancreatic enzyme preparations on erythrocyte glutathione peroxidase activities and plasma selenium concentrations in cystic fibrosis. [1998.07.15]
Desensitization to pancreatic enzyme intolerance in a child with cystic fibrosis. [1998.07]
Mismatch of duodenal deliveries of dietary fat and pancreatin from enterically coated microspheres. [1997.10]
Is fibrosing colonopathy an immune mediated disease? [1997.07]
13Carbon mixed triglyceride breath test and pancreatic enzyme supplementation in cystic fibrosis. [1997.04]
Response to a single oral dose of all-rac-alpha-tocopheryl acetate in patients with cystic fibrosis and in healthy individuals. [1996.05]
[Differential therapy of exocrine pancreatic insufficiency--current aspects and future prospects of substitution therapy with pancreatic enzymes] [1995.12]
Gut inflammation in children with cystic fibrosis on high-dose enzyme supplements. [1995.11.11]
Fibrosing colonopathy in cystic fibrosis: results of a case-control study. [1995.11.11]
Faecal interleukin-8 and tumour necrosis factor-alpha concentrations in cystic fibrosis. [1995.07]
Chronic metabolic alkalosis: not uncommon in young children with severe cystic fibrosis. [1995]
Pancolonic disease in cystic fibrosis and high-dose pancreatic enzyme therapy. [1994.10]
Strictures of ascending colon in cystic fibrosis and high-strength pancreatic enzymes. [1994.01.08]
[Long-term treatment of mucoviscidosis. Results with a microencapsulated pancreatic enzyme preparation] [1993.02.10]
Chronic pancreatitis. [1993.02]
Comparison between a standard pancreatic supplement and a high enzyme preparation in cystic fibrosis. [1992.10]
[Steatorrhea and its treatment with pancreatic enzymes in endocrine tumors of the pancreas (pancreatic adenomas)] [1990.07]
Postoperative management of patients with total exocrine pancreatic insufficiency. [1990.06]
Treatment failure after substitution of generic pancrelipase capsules. Correlation with in vitro lipase activity. [1990.05.09]
|
